Division of Endoscopy, Yamagata University Hospital, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
World J Gastroenterol. 2010 Mar 14;16(10):1252-7. doi: 10.3748/wjg.v16.i10.1252.
To investigate the association between adiponectin levels and risk of colorectal adenoma and cancer (early and advanced).
A cross-sectional study in a cohort of hospital-based patients was conducted between January 2004 and March 2006 at Yamagata University Hospital. Male subjects, who had colorectal tumors detected by endoscopic examination, were enrolled according to inclusion and exclusion criteria. Based on the T factor of the TNM system, intraepithelial carcinoma and submucosally invasive carcinoma were defined as early cancer, and invasion into the muscularis propria or deeper was defined as advanced cancer. The plasma levels of glucose, insulin, total cholesterol, triglyceride, high sensitivity C-reactive protein, insulin like growth factor (IGF)-1, IGF binding protein-3, adiponectin, leptin, and resistin were measured. Each factor level was designated low or high, and the risk of adenoma or cancer was estimated by univariate and multivariate logistic regression analysis.
We enrolled 124 male subjects (47 with adenoma, 34 with early cancer, 17 with advanced cancer, and 26 without tumors as controls). In patients with adenoma, high triglyceride and low adiponectin were associated with a significant increase in the odds ratio (OR) by univariate analysis. Only a low adiponectin level was related to increased adenoma risk, with an adjusted OR for low level (< 11 microg/mL) to high (>or=11 microg/mL) of 5.762 (95% confidence interval (CI): 1.683-19.739, P = 0.005). In the patients with early cancer, high body mass index, high triglyceride, and low adiponectin were associated with a significant increase in OR in univariate analysis. In multivariate analysis, only low adiponectin was significantly associated with early cancer, with an adjusted OR of 4.495 (95% CI: 1.090-18.528, P = 0.038). However, in patients with advanced cancer, low adiponectin was not recognized as a significant risk factor for advanced cancer.
A decreased level of adiponectin is strongly associated with an increased risk of colorectal adenoma and early cancer. These data call for further investigation, including a controlled prospective study.
探讨脂联素水平与结直肠腺瘤和癌症(早期和晚期)风险的关系。
这是一项 2004 年 1 月至 2006 年 3 月在山形大学医院进行的基于队列的医院患者的横断面研究。根据纳入和排除标准,招募内镜检查发现结直肠肿瘤的男性受试者。根据 TNM 系统的 T 因子,上皮内癌和黏膜下浸润癌定义为早期癌症,侵犯肌层或更深层定义为晚期癌症。测量血糖、胰岛素、总胆固醇、甘油三酯、高敏 C 反应蛋白、胰岛素样生长因子(IGF)-1、IGF 结合蛋白-3、脂联素、瘦素和抵抗素的血浆水平。将每个因素水平指定为低或高,并通过单变量和多变量逻辑回归分析估计腺瘤或癌症的风险。
我们共纳入 124 名男性受试者(47 名患有腺瘤,34 名患有早期癌症,17 名患有晚期癌症,26 名作为对照组无肿瘤)。在腺瘤患者中,单变量分析显示高甘油三酯和低脂联素与比值比(OR)显著增加相关。只有低脂联素水平与腺瘤风险增加相关,低水平(<11μg/mL)与高水平(≥11μg/mL)的调整 OR 为 5.762(95%置信区间(CI):1.683-19.739,P=0.005)。在早期癌症患者中,高体重指数、高甘油三酯和低脂联素与 OR 在单变量分析中显著增加相关。在多变量分析中,只有低脂联素与早期癌症显著相关,调整后的 OR 为 4.495(95%CI:1.090-18.528,P=0.038)。然而,在晚期癌症患者中,低脂联素未被认为是晚期癌症的显著危险因素。
脂联素水平降低与结直肠腺瘤和早期癌症的风险增加密切相关。这些数据呼吁进一步研究,包括对照前瞻性研究。